Wednesday, August 25, 2021

Bluefront Equity invests in AquaBioTech Group

AquaBioTech Group and Bluefront Equity have announced that they have entered into a letter of intent whereby Bluefront Equity will acquire a significant stake in the company through a combination of purchase of shares and new capital to accelerate the growth.

The planned investment by Bluefront Equity will enable AquaBioTech Group to continue to rapidly develop its international expansion plans, including the opening of a major office in Norway and Singapore.
 
Image credit: Apasciuto on Flickr
(CC BY 2.0)


AquaBioTech Group consists of three main divisions. The first is an aquaculture, fisheries and marine environment consulting, advisory and training company with offices in five countries serving hundreds of international clients.

The second is the Contract Research Organisation (CRO) division, which has grown to become one of the largest licensed aquatic CRO facilities in the European Union (EU) with more than fifty research RAS units in operation. The facility is used by all of the major vetriceutical, nutraceutical and aquatic nutrition companies for the testing, development and certification of aquatic vaccines and shrimp / fish feeds.

The third is an engineering and development company focused on the turnkey supply of Recirculation Aquaculture Systems (RAS) for commercial and research purposes that are designed for a variety of fish and shrimp species, including Salmon hatcheries, nurseries and grow-out facilities.

Visit the Aqua Bio Tech website, HERE.
Visit the Bluefront Equity website, HERE.


The Aquaculturists

No comments:

Post a Comment